OREXIGEN THERAPEUTICS INC's ticker is and the CUSIP is 686164AB0. A total of 3 filers reported holding OREXIGEN THERAPEUTICS INC in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $2,780,000,000 | -7.3% | 7,500,000 | 0.0% | 0.05% | +11.4% |
| Q3 2017 | $3,000,000,000 | 0.0% | 7,500,000 | 0.0% | 0.04% | -10.2% |
| Q2 2017 | $3,000,000,000 | 0.0% | 7,500,000 | 0.0% | 0.05% | -3.9% |
| Q1 2017 | $3,000,000,000 | -20.0% | 7,500,000 | -50.0% | 0.05% | -29.2% |
| Q4 2016 | $3,750,000,000 | -36.8% | 15,000,000 | -30.0% | 0.07% | -18.2% |
| Q3 2016 | $5,934,000,000 | -29.8% | 21,414,000 | 0.0% | 0.09% | -51.6% |
| Q2 2016 | $8,452,000,000 | -5.8% | 21,414,000 | 0.0% | 0.18% | +10.3% |
| Q1 2016 | $8,975,000,000 | -28.3% | 21,414,000 | +3.6% | 0.16% | -21.8% |
| Q4 2015 | $12,519,000,000 | -6.8% | 20,664,000 | +8.3% | 0.21% | -23.0% |
| Q3 2015 | $13,438,000,000 | -10.0% | 19,075,000 | +18.7% | 0.27% | +5.8% |
| Q2 2015 | $14,928,000,000 | -13.3% | 16,075,000 | +7.2% | 0.26% | -29.6% |
| Q1 2015 | $17,219,000,000 | +79.8% | 15,000,000 | +57.9% | 0.37% | +120.4% |
| Q4 2014 | $9,579,000,000 | – | 9,500,000 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 10,000,000 | $5,025,000 | 0.78% |
| GLG LLC | 4,960,000 | $2,480,000 | 0.15% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 7,500,000 | $3,000,000,000 | 0.05% |